Skip to main content
TipRanks
Go Ultimate75% OFF

Active Biotech Updates Share Count Following Reverse Split

Active Biotech Updates Share Count Following Reverse Split
Image source: Shutterstock

Active Biotech AB ( (SE:ACTI) ) just unveiled an announcement.

Active Biotech AB, traded on NASDAQ Stockholm, is a biotechnology company dedicated to first-in-class immunomodulatory therapies targeting oncology and immunology indications with substantial unmet medical need. Its pipeline centers on tasquinimod for myelofibrosis, laquinimod for non-infectious uveitis, and the partnered cancer immunotherapy naptumomab, all positioned in specialized, high-potential therapeutic areas.

The company announced that its total number of shares and voting rights has changed following a reverse share split approved at its Annual General Meeting, leaving 26,360,671 shares and votes outstanding as of the last trading day of the month. The adjustment in capital structure may affect trading dynamics and investor perception, as it recalibrates the share base while signaling management’s intent to optimize the company’s market presence under Sweden’s Financial Instruments Trading Act disclosure requirements.

More about Active Biotech AB

Active Biotech AB, listed on NASDAQ Stockholm under the ticker ACTI, is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications with high unmet medical need and significant commercial potential. Its core programs include tasquinimod for myelofibrosis, laquinimod for non-infectious uveitis, and naptumomab, a targeted anti-cancer immunotherapy partnered with NeoTX Therapeutics and currently in phase Ib/II trials.

The company is advancing tasquinimod through clinical proof-of-concept studies in a rare blood cancer, while laquinimod has completed a phase I ophthalmic program to support further phase II development with a partner. Naptumomab is being evaluated in patients with advanced solid tumors, underlining Active Biotech’s strategic focus on niche, high-need indications where innovative immunomodulatory therapies can capture meaningful clinical and commercial opportunities.

Average Trading Volume: 310,803

Technical Sentiment Signal: Sell

Current Market Cap: SEK153.9M

See more insights into ACTI stock on TipRanks’ Stock Analysis page.

This article was AI-generated from the company’s official filing, with automated quality checks and editorial spot-checks.

Disclaimer & DisclosureReport an Issue

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!